Overexpression of YKL-40 Predicts Plaque Instability in Carotid Atherosclerosis with CagA-Positive Helicobacter Pylori Infection

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wu, Yina ^a   Tao, Zhen ^b   Song, Chao ^a   Jia, Qingshuai ^c   Bai, Jun ^d   Zhi, Kangkang ^d   Qu, Lefeng ^d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c Center for Disease Prevention and Control of Jinan Military Command   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CAGA PROTEIN; CLARITHROMYCIN; GLYCOPROTEIN GP 39; OMEPRAZOLE; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ATHEROSCLEROSIS; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MONITORING; FEMALE; GENE OVEREXPRESSION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RABBIT; TREATMENT OUTCOME;

ADIPOKINES; AGED; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; HELICOBACTER INFECTIONS; HUMANS; LECTINS; MALE; MIDDLE AGED; OMEPRAZOLE; PLAQUE, ATHEROSCLEROTIC; RABBITS; UP-REGULATION;

ANIMALIA; HELICOBACTER PYLORI; ORYCTOLAGUS CUNICULUS;

EID: 84875736002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059996     Document Type: Article

References (18)

1. Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, et al. (2002) Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation 106: 580-584.
2. Gabrielli M, (2004) CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. European Heart Journal 25: 64-68.
3. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, et al. (1999) Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 19: 687-694.
4. Millis AJ, Hoyle M, Reich E, Mann DM, (1985) Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem 260: 3754-3761.
5. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, et al. (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110: 351-360.
6. Rathcke CN, Vestergaard H, (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55: 221-227.
7. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S, (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18: 391-396.
8. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, et al. (2008) YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42: 295-302.
9. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, et al. (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal 30: 1066-1072.
10. Zheng JL, Lu L, Hu J, Zhang RY, Zhang Q, et al. (2010) Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 210: 590-595.
11. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35-41.
12. Ge S, Zhou G, Cheng S, Liu D, Xu J, et al. (2009) Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 205: 74-79.
13. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM, (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20: 1262-1275.
14. Mayr M, Kiechl S, Mendall MA, Willeit J, Wick G, et al. (2003) Increased Risk of Atherosclerosis Is Confined to CagA-Positive Helicobacter pylori Strains: Prospective Results From the Bruneck Study. Stroke 34: 610-615.
15. DU Yiqi XG, JI Xuhuai (1999) Distribution of H.pylori cagA gene among Chinese and its clinical significance. Chinese Journal of Digestion 19.
16. Biasillo G, Leo M, Della Bona R, Biasucci LM, (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 5: 225-233.
17. Olsen MH, Sehestedt T, Lyngbaek S, Hansen TW, Rasmussen S, et al. (2010) Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide-three new cardiovascular risk markers-do they improve risk prediction and influence treatment? Curr Vasc Pharmacol 8: 134-139.
18. Morrow DA, de Lemos JA, (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115: 949-952.